Superior Cave Syndrome and Primary Bronchopulmonary Cancer

Bronchopulmonary cancer (PBC) is the leading cause of superior cell carcinoma (SCC). This study aims to establish a clinical, radiological and evolutionary profile of SCS associated with PBC, to examine therapeutic management modalities, and to evaluate survival while identifying and analyzing prognostic factors.This is a retrospective study of patients followed for SCS secondary to primary bronchopulmonary cancer. In 41.7% of cases, SCS was the first presenting sign of the neoplasia, while 16.6% presented with SCS metachronously. The histological type most frequently associated with SCS was small-cell lung carcinoma (40.7%).Contrast-enhanced thoracic computed tomography (CT) is the key examination for the diagnosis of SCS. The most common CT finding was tumor invasion of the superior vena cava (62.2%). Short-term prognosis depends on the consequences of cerebral and laryngeal edema and associated complications, while long-term prognosis is mainly influenced by the underlying etiology.